Quarterly report · Q2
3353.TEDINET S100PCTW
Period2022-03-01 → 2022-08-31
Filed2022-10-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥17.0bn | 2022-03-01 → 2022-08-31 | Cons. | Net sales |
| Revenue | ¥33.6bn | 2021-03-01 → 2022-02-28 | Cons. | Net sales (5-year summary) |
| Revenue | ¥16.8bn | 2021-03-01 → 2021-08-31 | Cons. | Net sales |
| Operating income | ¥466m | 2022-03-01 → 2022-08-31 | Cons. | Operating income |
| Operating income | ¥645m | 2021-03-01 → 2021-08-31 | Cons. | Operating income |
| Ordinary income | ¥598m | 2022-03-01 → 2022-08-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.4bn | 2021-03-01 → 2022-02-28 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥682m | 2021-03-01 → 2021-08-31 | Cons. | Ordinary income |
| Profit before tax | ¥624m | 2022-03-01 → 2022-08-31 | Cons. | Income before income taxes |
| Profit before tax | ¥781m | 2021-03-01 → 2021-08-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥374m | 2022-03-01 → 2022-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥852m | 2021-03-01 → 2022-02-28 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥444m | 2021-03-01 → 2021-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥386m | 2022-03-01 → 2022-08-31 | Cons. | Profit loss |
| Net income | ¥452m | 2021-03-01 → 2021-08-31 | Cons. | Profit loss |
| Total assets | ¥28.3bn | at 2022-08-31 | Cons. | Assets |
| Total assets | ¥29.1bn | at 2022-02-28 | Cons. | Assets |
| Total assets | ¥30.2bn | at 2021-08-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥16.1bn | at 2022-08-31 | Cons. | Liabilities |
| Total liabilities | ¥17.2bn | at 2022-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥12.2bn | at 2022-08-31 | Cons. | Net assets |
| Net assets / equity | ¥11.9bn | at 2022-02-28 | Cons. | Net assets |
| Net assets / equity | ¥11.6bn | at 2021-08-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.0bn | at 2022-08-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥8.0bn | at 2022-02-28 | Cons. | Cash and deposits |
| Cash & equivalents | ¥6.8bn | at 2022-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.8bn | at 2022-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.4bn | at 2021-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.8bn | at 2021-02-28d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥496m | 2022-03-01 → 2022-08-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.1bn | 2021-03-01 → 2022-02-28 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥334m | 2021-03-01 → 2021-08-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥291m | 2022-03-01 → 2022-08-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥216m | 2021-03-01 → 2022-02-28 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥47m | 2021-03-01 → 2021-08-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.2bn | 2022-03-01 → 2022-08-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥65m | 2021-03-01 → 2022-02-28 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.3bn | 2021-03-01 → 2021-08-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥99.65 | 2022-03-01 → 2022-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.26 | 2022-06-01 → 2022-08-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥226.92 | 2021-03-01 → 2022-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.22 | 2021-03-01 → 2021-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥58.13 | 2021-06-01 → 2021-08-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 41.2% | at 2022-08-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.1% | at 2022-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.6% | at 2021-08-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-03-01 → 2022-08-31 | −¥497m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-03-01 → 2022-08-31 | −¥497m |
| Reconciling Itemsreconciling | segment profit | 2022-03-01 → 2022-08-31 | −¥385m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥11.6bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥11.6bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥736m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥35m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥1.9bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥1.4bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥495m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥20m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥95m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥94m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥876,000 |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥61m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-03-01 → 2022-08-31 | ¥17.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-03-01 → 2022-08-31 | ¥17.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥497m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-03-01 → 2022-08-31 | ¥851m |
| Reconciling Itemsreconciling | revenue | 2021-03-01 → 2021-08-31 | −¥545m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-03-01 → 2021-08-31 | −¥545m |
| Reconciling Itemsreconciling | segment profit | 2021-03-01 → 2021-08-31 | −¥347m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2021-03-01 → 2021-08-31 | ¥11.3bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2021-03-01 → 2021-08-31 | ¥11.3bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2021-03-01 → 2021-08-31 | ¥731m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2021-03-01 → 2021-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2021-03-01 → 2021-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2021-03-01 → 2021-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2021-03-01 → 2021-08-31 | ¥146m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2021-03-01 → 2021-08-31 | ¥2.0bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2021-03-01 → 2021-08-31 | ¥1.4bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2021-03-01 → 2021-08-31 | ¥543m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2021-03-01 → 2021-08-31 | ¥50m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2021-03-01 → 2021-08-31 | ¥117m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2021-03-01 → 2021-08-31 | ¥116m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2021-03-01 → 2021-08-31 | ¥960,000 |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2021-03-01 → 2021-08-31 | ¥65m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-03-01 → 2021-08-31 | ¥17.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-03-01 → 2021-08-31 | ¥16.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-03-01 → 2021-08-31 | ¥545m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-03-01 → 2021-08-31 | ¥992m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 501
| Item | Context | Value | Unit |
|---|---|---|---|
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |